Capforce Inc (CFOR) Return on Equity ROE from the second quarter 2026 to second quarter 2025 and annually, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Capforce Inc   (CFOR)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare

Capforce Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Capforce Inc in the second quarter 2026?
Capforce Inc achieved a return on average equity (ROE) of 168.5 % in its second quarter 2026, this is above CFOR's average return on equity of -303.32%.
Capforce Inc shareholder's equity over the 12 months ending in its second quarter 2026 are valued at $37 million

ROE has advanced compared to 110.42% in the first quarter 2026, due to net income growth.

Within the Medical Laboratories industry Capforce Inc achieved the highest return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2026 from 0 to 92.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Equity Change 596.42 % 343.08 % 331.63 % 240.16 % -
Y / Y Net Income Change 1117.35 % - 375.24 % - -
Net Income (TTM) in Millions 62 23 23 7 16
Return On Equity (TTM) 168.5 % 110.42 % 157.18 % 78.18 % 224.17 %
CFOR's Total Ranking # 92 # 0 # 0 # #
Equity (TTM) in Millions 74 31 32 10 11
Seq. Equity Change 137.64 % -1.89 % 213.61 % -4.76 % 51.19 %
Seq. Net Income Change - - - - -

Back to CFOR Management Effectiveness >> CFOR's 5 Years Annual ROE >> Compare CFOR ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 0
Sector # 11
Overall # 92

Return On Equity Statistics
High Average Low
742.24 %
-303.32 %
-1827.04 %
(Mar 31 2025)   (Dec 31 2023)





CFOR Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Equity in Millions 32 7 -12 8 41
Y / Y Equity Change 331.63 % - - -81.62 % 94.5 %
Net Income in Millions 23 11 -33 -37 -35
Y / Y Net Income Change 106.75 % - - - -
Return On Equity 73.7 % 153.86 % - -492.15 % -84.44 %

Back to CFOR Management Effectiveness >> CFOR's 5 Years Annual ROE >> Compare CFOR ROE to its Competitors




Annual Roe Comment
In 2025 ROE fell to 73.7 %, despite net income growth.


More Return On Equity Ratios
Medical Laboratories Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
CFOR's' Return on Equity at Yahoo Finance
CFOR's Roe Ratio versus Medical Laboratories Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for CFOR's Competitors
Subscribers only: Roe for Capforce Inc 's Suppliers
Subscribers only: Return On Equity for CFOR's Customers




Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector ROE
Silexion Therapeutics Corp  276.59 %
Actinium Pharmaceuticals Inc  213.46 %
Capforce Inc   168.50 %
Interpace Biosciences Inc   142.98 %
Oncotelic Therapeutics Inc   124.17 %
Medpace Holdings Inc   110.15 %
Rigel Pharmaceuticals Inc  96.49 %
3m Company  76.55 %
Oramed Pharmaceuticals Inc  73.03 %
Idexx Laboratories Inc  71.96 %
Elite Pharmaceuticals Inc   71.10 %
Earth Science Tech Inc   66.17 %
Vaxart Inc   53.04 %
Tenet Healthcare Corp  50.64 %
Nrc Health  48.29 %

Date modified: 2026-08-20T07:46:22+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.